Poolbeg Pharma (LSE:POLB) has reported interim safety data from its ongoing TOPICAL clinical trial of POLB 001, with an independent review recommending that the study continue without changes.
The trial is evaluating POLB 001 as a preventative treatment for Cytokine Release Syndrome in patients with relapsed or refractory multiple myeloma receiving the bispecific antibody teclistamab.
Following the safety review, patient recruitment will continue at participating UK clinical sites, while Poolbeg plans to activate additional centres.
Independent Review Recommends Trial Continue Without Changes
The interim review assessed safety data generated during the ongoing TOPICAL study.
Based on the data reviewed, the independent assessment recommended that the trial proceed without modifications.
The update relates to safety and does not establish the efficacy of POLB 001 in preventing Cytokine Release Syndrome. The clinical trial remains ongoing.
Poolbeg Continues POLB 001 Development
POLB 001 is being developed to prevent Cytokine Release Syndrome, a complication that can occur with certain cancer immunotherapies.
Poolbeg is evaluating whether preventing the condition could support the use of treatments such as bispecific antibodies in a broader range of clinical settings.
The company said it intends to share emerging data from the programme with prospective partners as development progresses.
Poolbeg Pharma Pipeline
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing treatments in cancer immunotherapy and other therapeutic areas.
POLB 001 is its lead clinical asset and is being evaluated for the prevention of Cytokine Release Syndrome associated with cancer immunotherapies.
The company’s development pipeline also includes an oral GLP-1 programme targeting obesity.
Leave a Reply